Hepatitis Forums
Hepatitis C Main Forums => Hepatitis C Research News & Studies => Topic started by: Hep Editors on August 26, 2014, 11:33:44 am
-
Sovaldi currently has 70 percent of the hep C market share. Janssen’s Olysio (simeprevir), meanwhile, has a market share of nearly a quarter; it is mostly being prescribed in combination with Sovaldi.
Surveys also show that many clinicians are still in the dark about emerging hep C therapies.
Read more: http://www.hepmag.com/articles/Sovaldi_ledipasvir_domination_2501_26069.shtml